RocRock Bio participated in the "Transcriptome complexity in human disease" meeting organized by the STINT-NSFC Network at Engsholms Slott Castle in Sweden from May 10th to 12th. This meeting gathered experts from institutions such as SciLifeLab, Karolinska Institutet, Stockholm University, Huazhong University of Science and Technology, and Lingang Laboratory, to discuss the complexity of transcriptomes in human diseases.
A three-day discussion meeting brought together experts, researchers, and business representatives from the fields of biology and cells globally to focus on the issue of transcriptome complexity in human diseases. During the meeting, RocRock Bio and Karolinska Institutet agreed to launch the Bluesky project for CAR-M cell drug development and jointly advance a large-scale screening project for the CAR-M phagocytosis platform. This deep cooperation will bring more hope to patients with solid tumors worldwide and inject new possibilities into the future of cell therapy, promoting the progress of human health.
CAR-T therapy has achieved remarkable results in blood tumor treatment, yet cell therapy for solid tumors remains in the experimental stage. Recently, macrophages have gained attention from researchers worldwide due to their unique abilities to kill cancer cells and penetrate tumors. Dr. Xiushan Yin, co-founder of RocRock Bio, presented the company's innovative CAR-M virus delivery platform and shared his vision for the future of cell therapy as a global leader in CAR-M. CAR-M holds great market potential and is expected to provide more precise and effective treatment options for patients. RocRock Bio is committed to increasing R&D investment to develop more innovative cell therapy products for patients globally.
The Showcase of Success at the STINT-NSFC closed - door discussion meeting has breathed new life into global research and industry focused on human disease transcriptome complexity. RocRock Bio, as an innovative company pioneering solid tumor targeted therapy development, is dedicated to launching two innovative drugs in 5 - 6 years, aiming to extend solid tumor patients' lives by 24 years.
Offline Website Software